Drug Profile
Carbidopa/oxytriptan - Evecxia
Alternative Names: EVX-101Latest Information Update: 05 Oct 2023
Price :
$50
*
At a glance
- Originator Evecxia
- Class Antidepressants; Small molecules; Tryptamines
- Mechanism of Action Decarboxylase inhibitors; Serotonin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Depressive disorders
Most Recent Events
- 05 Oct 2023 9399661 - KDM updated, scientific data and HE added, trial initiation FE added
- 02 Oct 2023 Adverse events data from preclinical trial in Depressive disorders released by Evecxia Therapeutics
- 02 Oct 2023 Evecxia Therapeutics plans phase-II trial for Major depressive disorder (Adjunctive treatment) in the Q1 2024 (PO) (Evecxia Therapeutics pipeline; October 2023)